Neuropsychological Late Effects of Pediatric Cancer Treatment
Globally, over 300,000 children are diagnosed with cancer annually. Treatments continue to improve, and children and adolescents are surviving at higher rates. Nonetheless, morbidities of cancer and treatment persist. This includes altered trajectories of cognitive development, executive functions, processing speed, visual-spatial skills, and mood. While those who have experienced a pediatric brain tumor are at greatest risk for neuropsychological late effects, those diagnosed with hematological malignancies or solid organ tumors also experience late effects of cancer and therapies. The team at CHOP has a multitiered surveillance and intervention model to monitor for neuropsychological late effects in accordance with the Standards for the Psychosocial Care of Children With Cancer and Their Families.
In this lecture a CHOP expert in late effects will:
ACCME Accreditation Statement: Children’s Hospital of Philadelphia is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Approval of AMA PRA Category 1 Credit(s) for this lecture is pending. If approved, physicians can claim CME credit commensurate with the extent of their participation in the activity for free.
Related specialties: oncology, hematology, neurology, general pediatrics